Technical CommentsCancer

Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”

See allHide authors and affiliations

Science Translational Medicine  24 May 2017:
Vol. 9, Issue 391, eaal2439
DOI: 10.1126/scitranslmed.aal2439


Although the combination of decitabine and platinum drugs may be promising for therapy of renal cell carcinoma, the role of OCT2 needs further investigations.

View Full Text

Stay Connected to Science Translational Medicine